Moomoo AI 已提取核心信息
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
NexImmune, Inc.已与Cantor Fitzgerald & Co. 和BTIG, LLC共同达成协议，自2024年2月2日起终止其受控股权发行SM销售协议和相关的 “市场” 发行计划（ATM计划）。该协议最初于2022年6月披露，允许NexImmune以5000万美元的总发行价出售其普通股。在终止之前，NexImmune成功出售了127,396股股票，净收益约为510万美元。销售协议和自动柜员机计划的终止不涉及对公司的任何重大提前解雇处罚。2022年6月17日向美国证券交易委员会提交的8-K表格中提到了销售协议的更多细节。
NexImmune, Inc.已与Cantor Fitzgerald & Co. 和BTIG, LLC共同达成协议，自2024年2月2日起终止其受控股权发行SM销售协议和相关的 “市场” 发行计划（ATM计划）。该协议最初于2022年6月披露，允许NexImmune以5000万美元的总发行价出售其普通股。在终止之前，NexImmune成功出售了127,396股股票，净收益约为510万美元。销售协议和自动柜员机计划的终止不涉及对公司的任何重大提前解雇处罚。2022年6月17日向美国证券交易委员会提交的8-K表格中提到了销售协议的更多细节。
有用
没用